Drug Type Universal CAR-T |
Synonyms |
Target |
Mechanism T-cell surface glycoprotein CD5 inhibitors |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 | CN | 27 Jul 2022 | |
T-cell Acute Lymphoblastic Leukemia/Lymphoma | Phase 1 | CN | 27 Jul 2022 | |
Refractory T Acute Lymphoblastic Leukemia | Phase 1 | CN | 14 Sep 2021 |
NCT05032599 (EHA2024) Manual | Phase 1 | 16 | (ktbdlhslrz) = Adverse events within 30 days included grade 3-4 cytopenias (100%, 92% of which were present prior tolymphodepletion), grade 1-2 cytokine release syndrome (75%), grade 1-2 neurotoxicity (25%) and grade 1 skingraft-versus-host disease (GVHD)(69%) and one grade 3 infection (6%) with no dose-limiting toxicity. rkhbwweeax (mxjgeelwhy ) | Positive | 14 May 2024 | ||
(received SCT at 35) | |||||||
NCT05032599 (ASCO2022) Manual | Phase 1 | 5 | (qlspdhamid) = zhfhuqgcyd psvmoumrdh (wwinmjnqae ) View more | Positive | 02 Jun 2022 |